Treatment of hospital-acquired methicillin-resistant staphylococcus aureus infections.
DOI:
https://doi.org/10.35954/SM2022.41.2.3.e401Keywords:
practice guideline, cross infection, drug therapy, methicillin-resistant staphylococcus aureusAbstract
Introduction: infection by methicillin-resistant Staphylococcus aureus, one of the main bacteria causing hospital infections, has become a worldwide concern due to the high morbidity and mortality rate it produces. Bacterial resistance is a factor that aggravates the problem of hospital infections and is mainly associated with the inappropriate use of antibiotics. The prudent use of antibiotics helps to control bacterial resistance; however, more and more strains resistant to different antibiotics are being detected. A review of available antibiotic treatments for hospital infections caused by methicillin-resistant Staphylococcus aureus in adult patients was carried out in order to provide a guide for a rational use of available antibiotics, thus avoiding further development of the phenomenon of bacterial resistance. Methodology: an observational, descriptive, literature review type study was carried out, restricting the search to clinical practice guidelines. In order to know the existing guidelines in Uruguay, the Department of Infectious Diseases of the School of Medicine, University of the Republic and the Ministry of Public Health were consulted. Guidelines from different countries were found and analyzed. There is agreement on the general guidelines for pharmacological treatment of hospital infections caused by methicillin-resistant Staphylococcus aureus. Results: in Uruguay there are no guidelines for the treatment of hospital infections caused by methicillin-resistant Staphylococcus aureus. The guidelines published by the Infectious Diseases Society of America are used as a reference. Discussion: some of the antibiotics recommended in the guidelines analyzed are not available in our country, as is the case of daptomycin, telavancin and cloxacillin. In particular, the unavailability of daptomycin could make the treatment of infections in which the MIC of vancomycin is higher than 1.5 mg/L more difficult. Conclusions: therefore, it is considered convenient and necessary to establish guidelines for the treatment of such infections, according to the possibilities, to the epidemiology of our country and to the resistance patterns to this bacterium, in order to unify clinical practice and make a rational use of antibiotics so as to avoid promoting the phenomenon of microbial resistance.
Received for review: June 2022.
Accepted for publication: July 2022.
Correspondence: Av. 8 de Octubre 3020. Tel: (+598) 24876666 ext. 1663.
Contact e-mail: mpoggi@dnsffaa.gub.uy
Downloads
References
Echevarria J, Iglesias D. Estafilococo Meticilino resistente, un problema actual en la emergencia de resistencia entre los Gram positivos. Rev Med Hered [Internet]. 2003 [Consultado 18 de marzo 2022]; 14(4):195-203. Disponible en: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1018-130X2003000400008&lng=es
Rodriguez J, Cisneros J, Moreno I, Salas J, Pascual A. Documento de consenso sobre el manejo clínico de las infecciones causadas por Staphylococcus aureus resistente a meticilina en adultos. [Internet]. Sociedad Andaluza de Enfermedades Infecciosas. 2004 [Consultado 18 de marzo 2022]. Disponible en: https://www.saei.org/
Gaviria J. Factores de riesgo asociados con la infección por Staphylococcus aureus meticilino resistente relacionados con la atención del paciente. Hospital Pablo Tobon Uribe 2005-2008. [Tesis de Maestría]. Medellín, Universidad CES; 2008.
Ramírez R, Robustillo A, Sainz de los Terreros L. Epidemiología de la Infección Nosocomial. En: Prevención y control de la infección nosocomial. Comunidad de Madrid; 2008, p. 1-10. Disponible en: https://www.madrid.org/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-disposition&blobheadername2=cadena&blobheadervalue1=filename%3DGuiaBPC-+Infecci%C3%B3n+Nosocommial+5+mayo+2009.pdf&blobheadervalue2=language%3Des%26site%3DPortalSa-lud&blobkey=id&blobtable=MungoBlobs&blobwhere=1220487126351&ssbinary=true
Pujol M, Limón E. Epidemiología general de las infecciones nosocomiales. Sistemas y programas de vigilancia. Enferm Infecc Microbiol Clín [Internet]. 2013 [Consultado 18 de marzo 2022]; 31(2):108-113. Disponible en: https://seimc.org/contenidos/documentoscientificos/eimc/seimc_eimc_v31n02p108a113.pdf
Gil M. Staphylococcus aureus: Microbiología y aspectos moleculares de la resistencia a meticilina. Rev Chil Infect [Internet]. 2000 [Consultado 18 de marzo 2022]; 17(2):145-152. Disponible en: https://www.scielo.cl/pdf/rci/v17n2/art10.pdf
Pérez C. Medición de niveles plasmáticos. Rev. chil. infectol. [Internet]. 2002 [Consultado 18 de marzo 2022]; 19(1):33-37. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0716-10182002019100006&lng=es http://dx.doi.org/10.4067/S0716-10182002019100006
Gudiol F, Aguado J, Pascual A, Pujol M, Almirante B, Miró J, et al. Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina. Enferm Infecc Microbiol Clín [Internet]. 2009 [Consultado 18 de Julio 2022]; 27(2):105-115. Disponible en: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-pdf-S0213005X08000190
Jimeno J, Figuerola A, Padilla B, Grande F. Medidas de aislamiento para pacientes con enfermedades infectocontagiosas. En: Prevención y control de la infección nosocomial. Comunidad de Madrid; 2008, p. 191-211. Disponible en: http://www.madrid.org/cs/Satellitec=PTSA_Multimedia_FA&cid=1142547800759&page-name=PortalSalud%2FPTSA_Multimedia_FA%2FPTSA_documentoWebeditpro
Camarena J, Sánchez R. Infección por Staphylococcus aureus resistente a meticilina. [Internet]. Control de Calidad del SEIMC. 1998 [Consultado 18 de marzo 2022]. Disponible en: https://www.seimc.org/contenidos/ccs/revisionestematicas/bacteriologia/sarm.pdf
Bonino A, Gnesetti A, Pujadas M, BroggiI A. Infecciones por Staphylococcus aureus meticilino resistente adquirido en la comunidad: análisis de la población pediátrica asistido en el Hospital Policial de Uruguay, 2004. Arch Pediatr Urug [Internet]. 2007 [Consultado 18 de marzo 2022]; 78(1):41-47. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S1688-12492007000100008&lng=es Padilla B, Grande F, Cantón R, Ruiz P, San Juan R. Microorganismos multirresistentes y uso de antimicrobianos. En: Prevención y control de la infección nosocomial. Comunidad de Madrid; 2008, p. 213-239. Disponible en: https://www.madrid.org/cs/Satellite?blobcol=urldata&blobheader=application%2Fpdf&blobheadername1=Content-disposition&blobheadername2=cadena&blobheadervalue1=filename%3DGuiaBPC-+Infecci%C3%B3n+Nosocommial+5+mayo+2009.pdf&blobheadervalue2=language%3Des%26site%3DPortalSa-lud&blobkey=id&blobtable=MungoBlobs&blobwhere=1220487126351&ssbinary=true
Liu C, Bayer A, Cosgrove S, Daum R, Fridkin S, Gorwitz R, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis. [Internet]. 2011 [Consultado 3 de Abril 2022]; 52(3):18-55.
Mensa J, Barberan J, Llinares P, Picazo J, Bouza E, Alvzarez F, et al. Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina. Rev Esp Quimioter. [Internet]. 2008 [Consultado 3 de abril 2022]; 21(4):234-258.
Gemmell C, Edwards D, Fraise A, Gould F, Ridgway G, Warren R. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococccus aureus (MRSA) infections in the UK. J Antimicrob Chemother. [Internet]. 2006 [Consultado 3 de Abril 2022]; 57(4):589-608.
Gould F, Brindle R, Chadwick P, Fraise A, Hill S, Nathwandi D, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococccus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. [Internet]. 2009 [Consultado 3 de Abril 2022]; 63(5):849-861.
Ben RJ, Chan YJ, Chang FY, Chang SC, Chen PY, Chen YS, et al. Guidelines for the treatment of methicillin-resistant Staphylococccus aureus infections in Taiwan. J Microbiol Immunol Infect Journal. [Internet]. 2013 [Consultado 17 de Abril 2022]; 46(3):147-150.
Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Dominguez MA, et al. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. [Internet]. 2015 [Consultado 17 de Abril 2022]; 33(9):625.e1–625.e23.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mariana Poggi. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
